WO2018000324A1 - Procédé d'introduction d'un anticorps dans une cellule - Google Patents

Procédé d'introduction d'un anticorps dans une cellule Download PDF

Info

Publication number
WO2018000324A1
WO2018000324A1 PCT/CN2016/087889 CN2016087889W WO2018000324A1 WO 2018000324 A1 WO2018000324 A1 WO 2018000324A1 CN 2016087889 W CN2016087889 W CN 2016087889W WO 2018000324 A1 WO2018000324 A1 WO 2018000324A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cell
drug
tat
transmembrane peptide
Prior art date
Application number
PCT/CN2016/087889
Other languages
English (en)
Chinese (zh)
Inventor
张军方
Original Assignee
张军方
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 张军方 filed Critical 张军方
Priority to PCT/CN2016/087889 priority Critical patent/WO2018000324A1/fr
Priority to CN201680004036.4A priority patent/CN107223136B/zh
Publication of WO2018000324A1 publication Critical patent/WO2018000324A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Abstract

L'invention concerne un procédé permettant d'introduire un anticorps dans une cellule, ledit procédé consistant à exprimer par fusion un peptide transmembranaire et un anticorps. L'anticorps peut traverser la membrane cellulaire et pénétrer dans la cellule pour se lier à une molécule cible. L'anticorps conserve également une propriété spécifique de liaison à l'antigène. Le procédé introduit avec succès l'anticorps dans la cellule à l'aide du peptide transmembranaire exprimé par fusion, et exerce un effet d'anticorps intracellulaire. Le procédé selon l'invention permet d'exécuter une thérapie ciblée au moyen d'anticorps intracellulaires et d'augmenter de manière significative l'effet curatif du traitement.
PCT/CN2016/087889 2016-06-30 2016-06-30 Procédé d'introduction d'un anticorps dans une cellule WO2018000324A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/087889 WO2018000324A1 (fr) 2016-06-30 2016-06-30 Procédé d'introduction d'un anticorps dans une cellule
CN201680004036.4A CN107223136B (zh) 2016-06-30 2016-06-30 一种将抗体导入细胞内的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/087889 WO2018000324A1 (fr) 2016-06-30 2016-06-30 Procédé d'introduction d'un anticorps dans une cellule

Publications (1)

Publication Number Publication Date
WO2018000324A1 true WO2018000324A1 (fr) 2018-01-04

Family

ID=59927634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/087889 WO2018000324A1 (fr) 2016-06-30 2016-06-30 Procédé d'introduction d'un anticorps dans une cellule

Country Status (2)

Country Link
CN (1) CN107223136B (fr)
WO (1) WO2018000324A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076954A1 (fr) * 2018-10-09 2020-04-16 Ibex Biosciences, Llc Anticorps dirigés contre la filamine-a et leurs utilisations thérapeutiques

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020029123A1 (fr) * 2018-08-08 2020-02-13 深圳宣泽生物医药有限公司 Méthode de modification des vésicules extracellulaires
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
CN111537744B (zh) * 2020-05-26 2023-04-07 上海交通大学医学院附属上海儿童医学中心 一种基于乳脂肪球膜特性的乳凝集素或粘蛋白1的elisa定量检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129033A2 (fr) * 2009-04-29 2010-11-11 Calmune Corporation Anticorps modifiés pour immunothérapie passive
CN104059153A (zh) * 2013-09-13 2014-09-24 西安交通大学医学院第一附属医院 一种靶向病毒核心蛋白的穿膜抗体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102030824A (zh) * 2009-09-30 2011-04-27 王虹 一种乙型肝炎病毒x蛋白单克隆抗体及用途
NZ704191A (en) * 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
CN103173478B (zh) * 2013-03-04 2015-09-09 西北大学 一种携带ptd的抗人cd3单链抗体的制备方法
CN105445460B (zh) * 2015-12-23 2018-01-02 中国人民解放军第二军医大学 一种抗乙肝病毒HBx单克隆抗体及其制备与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129033A2 (fr) * 2009-04-29 2010-11-11 Calmune Corporation Anticorps modifiés pour immunothérapie passive
CN104059153A (zh) * 2013-09-13 2014-09-24 西安交通大学医学院第一附属医院 一种靶向病毒核心蛋白的穿膜抗体及其制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ITAKURA: "Effective capture of proteins inside living cells by antibodies indirectly linked to a novel cell -penetrating polymer-modified protein A derivative", THE FEBS JOURNAL, vol. 282, 31 December 2015 (2015-12-31), pages 142 - 152 *
RIZZUTI ET AL.: "Therapeutic applications of the cell -penetrating HIV-1 Tat peptide", DRUG DISCOVERY TODAY, vol. 20, no. 1, 31 January 2015 (2015-01-31), pages 76 - 85, XP055600994, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2014.09.017 *
SHIN: "Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy", JOURNAL OF CONTROLLED RELEASE, vol. 194, 7 September 2014 (2014-09-07), pages 197 - 210, XP029088444, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2014.08.030 *
YE: "15 years of ATTEMPTS: Amacromolecular drug delivery systembasE on the CPP-mediated intracellular drug delivery and antibody targeting", JOURNAL OF CONTROLLED RELEASE, vol. 205, 4 December 2014 (2014-12-04), pages 58 - 69 *
ZHUANG: "A Cell -penetrating Antibody Fragment against HIV-1 Rev Has High Antiviral Activity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 29, 18 July 2014 (2014-07-18), pages 20222 - 20233 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076954A1 (fr) * 2018-10-09 2020-04-16 Ibex Biosciences, Llc Anticorps dirigés contre la filamine-a et leurs utilisations thérapeutiques
CN113164633A (zh) * 2018-10-09 2021-07-23 艾比克斯生物科学有限责任公司 针对细丝蛋白-a的抗体及其治疗用途
CN113164633B (zh) * 2018-10-09 2023-11-21 艾比克斯生物科学公司 针对细丝蛋白-a的抗体及其治疗用途

Also Published As

Publication number Publication date
CN107223136A (zh) 2017-09-29
CN107223136B (zh) 2020-12-25

Similar Documents

Publication Publication Date Title
Sadeqzadeh et al. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells
Niesner et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides
Anand et al. Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers
IL283969A (en) Cod20-binding immunotoxins for cellular induction and methods of use
US10156559B2 (en) Lipocalin fusion partners
US11273206B2 (en) Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
US9340616B2 (en) Methods and compositions for heptameric targeting ligands
WO2018000324A1 (fr) Procédé d'introduction d'un anticorps dans une cellule
WO2007036022A1 (fr) Administration ciblee de composes au moyen de la technologie de multimerisation
JP5677454B2 (ja) 細胞内ターゲット結合用二座ペプチドバインダー
JP2019528251A (ja) グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
US20190388549A1 (en) Targeted Protease Compositions and Uses Related Thereto
JP4912556B2 (ja) 細胞質内及び／又は細胞核内への対象物質の侵入を促進するペプチド
US11851496B2 (en) Antibodies against the human fshr extracellular domain
JP5677453B2 (ja) Ｂｐｂベースのカーゴ運搬システム
Niamsuphap et al. Targeting the undruggable: emerging technologies in antibody delivery against intracellular targets
Baranyai et al. Cellular internalization and inhibition capacity of new anti-glioma peptide conjugates: physicochemical characterization and evaluation on various monolayer-and 3D-spheroid-based in vitro platforms
Tansi et al. New generation CPPs show distinct selectivity for cancer and noncancer cells
Li et al. Intracellular antibody delivery mediated by lipids, polymers, and inorganic nanomaterials for therapeutic applications
WO2018060480A1 (fr) Anticorps anti-mésothéline
Zhang et al. Human Serum Albumin‐Based Drug‐Free Macromolecular Therapeutics: Apoptosis Induction by Coiled‐Coil‐Mediated Cross‐Linking of CD20 Antigens on Lymphoma B Cell Surface
Messerschmidt et al. Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling
US20180002439A1 (en) Anti-mesothelin antibodies and uses thereof
JP7386318B2 (ja) 体液性免疫抑制疾患の治療のための、体液性免疫抑制因子の拮抗薬の組成物および使用
Polli et al. Cell penetrating peptides conjugated to anti-carcinoembryonic antigen “catch-and-release” monoclonal antibodies alter plasma and tissue pharmacokinetics in colorectal cancer xenograft mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16906725

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/06/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 16906725

Country of ref document: EP

Kind code of ref document: A1